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Abstract: Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality
in women. The identification of risk factors can improve prevention of cancer, and obesity and
hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work,
we review the progress to date in research on the potential role of the main cholesterol transporters,
low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although
some studies have failed to find associations between lipoproteins and breast cancer, some large clinical
studies have demonstrated a direct association between LDL cholesterol levels and breast cancer
risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast
cancer cells and experimental mouse models of breast cancer have demonstrated an important role for
cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol
metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer
cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate
different inflammation-related pathways, thereby enhancing cell proliferation and migration and
inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as
potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
Keywords: Breast cancer; cholesterol; 27-hydroxycholesterol; HDL; LDL; cholesterol-lowering therapies
1. Introduction
Breast cancer is the third most common cancer overall, with an estimated incidence of 1.7 million
cases in 2016 and a 29% increase in incident cases between 2006 and 2016. Moreover, breast cancer
was the fifth leading cause of cancer deaths for both sexes in 2016 and the primary cause of death for
women [1]. A substantial proportion of the worldwide burden of cancer could be prevented; however,
improved primary prevention of cancer requires identification of risk markers [2]. Reproductive,
hormonal factors, and unhealthy lifestyles that trigger obesity are considered significant risk factors
for breast cancer [3]. Obesity represents a potentially modifiable risk factor that could increase the risk
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of breast cancer in women [4,5]. The biological association between obesity and disease risk, at least in
part, may be related to circulating lipid levels and tissue lipid metabolism [6].
Cancer cells show specific alterations in different aspects of lipid metabolism, which can affect
the availability of structural lipids for the synthesis of membranes, contribution of lipids to energy
homeostasis, and lipid signaling functions, including the activation of inflammation-related pathways.
All these changes are related to important cellular processes, including cell growth, proliferation,
differentiation, and motility [7]. The interplay among cholesterol, lipoproteins, proinflammatory
signaling pathways, and tumor development has mainly been studied in breast cancer cells and
experimental models in vivo. Furthermore, in humans, both benign and malignant proliferation of
breast tissue were associated with changes in plasma lipid and lipoprotein levels [8], despite that
epidemiological data on the association between lipoproteins and breast cancer showed inconclusive
results [9–11]. This article reviews the progress to date in research on the role of cholesterol and its
main lipoprotein transporters, the low-density and high-density lipoproteins (LDL and HDL), on
breast cancer development, mainly focusing on recent findings in human trials and those obtained in
experimental models of breast cancer. PubMed was searched comprehensively with combinations of
the keyword Breast Cancer and the rest of keywords related with cholesterol and lipoproteins.
2. Association of Cholesterol in Breast Cancer Risk: Clinical and Epidemiological Studies
Study of the relationship between serum cholesterol levels and risk of cancer is of special interest
and has sparked debate, especially with the expansion of lipid-modifying therapies and more aggressive
cholesterol goals to reduce the risk of cardiovascular events [12]. However, different studies have
produced divergent results. Indeed, one study found that total cholesterol was associated with the risk
of breast cancer [13], but others failed in finding such an association [14–18], or they even found that
total cholesterol was inversely associated with the risk of breast cancer [19].
Since cholesterol is mainly transported by LDL and HDL, several clinical trials have associated
them with breast cancer. A clinical study in which the lipid profile was assessed in women with breast
cancer showed that LDL cholesterol (LDL-C) levels at diagnosis was a prognostic factor of breast tumor
progression. A systemic LDL-C level above 117 mg dL−1 was found to be a predictive factor of tumor
stage, and it was positively associated with worse prognosis because of a higher histological grade,
higher proliferative rate, and more advanced clinical stage [20] (Table 1). Moreover, patients with
LDL-C above 144 mg dL−1 were also prone to have lymph node metastasis [20]. More importantly,
a Mendelian randomization study found that genetically raised LDL-C was associated with a higher
risk of breast cancer [11]. However, other meta-analyses and prospective studies found no association
between LDL-C and breast cancer risk [9,10,16,21]; some trials even found that LDL-C or non-HDL
were inversely associated with the risk of breast cancer [14,22] (Table 1).
Concerning HDL-C, discordant results were also found. One prospective study with a follow-up
time of 11.5 years found an inverse association between HDL-C and breast cancer risk [19],
and retrospectively collected clinical data showed that decreased HDL-C levels had a significant
association with worse overall survival in breast cancer patients [23] (Table 1). In contrast, a Mendelian
randomization study showed that raised HDL-C increased the risk of estrogen receptor (ER)-positive
breast cancer [11] (Table 1). It should also be noted that other studies failed to find any association
between HDL-C and breast cancer risk [10,21,24] or survival [24]. Moreover, controversy also exists
when considering the menopausal status of patients (Table 1). Some studies have found that low
HDL-C among premenopausal women increased breast cancer risk [9,25,26], while others found that
low HDL-C was associated with an increased postmenopausal risk of breast cancer [16,27].
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Table 1. Clinical and epidemiological studies linking low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein cholesterol (HDL-C) levels to breast cancer risk.
Reference Year Study Design Participants Main Findings
Nowak et al. [11] 2018 Mendelianrandomization >400,000
Raised LDL-C increased the risk of breast cancer
(OR = 1.09 (1.02–1.18)) and ER-positive breast cancer
(OR = 1.14 (1.05–1.24)).
Raised HDL-C increased the risk of ER-positive breast
cancer (OR = 1.13 (1.01–1.26)).
Ni et al. [16] 2015 Meta-analysis 1,189,635
Inverse association between HDL-C and breast cancer
risk among postmenopausal women (RR = 0.45
(0.64–0.93)). No association in premenopausal women.
No association between LDL-C and breast cancer risk.
Touvier et al. [9] 2015 Meta-analysis 1,489,484
Inverse association between HDL-C and breast cancer
risk among premenopausal women (HR = 0.77
(0.31–0.67)). No association in postmenopausal women.
No association between LDL-C and breast cancer risk.
Borgquist et al. [21] 2016 Prospective 5281 No evident associations between LDL-C or HDL-Cand breast cancer incidence.
Chandler et al. [10] 2016 Prospective 15,602 No association between LDL-C or HDL-C and breastcancer risk.
His et al. [19] 2014 Prospective 7557 HDL-C was inversely associated with breast cancerrisk (HR 1 mmol L−1 increment = 0.48 (0.28–0.83)).
Rodrigues dos
Santos et al. [20] 2014 Prospective 244
Systemic levels of LDL-C correlated positively with
tumor size (Spearman’s r = 0.199, p = 0.002).
Kucharska-Newton
et al. [25] 2008 Prospective 7575
Modest association of low HDL-C (<50 mg dL−1) with
breast cancer among premenopausal women
(HR = 1.67 (1.06–2.63)). No association in
postmenopausal women.
Furberg et al. [27] 2004 Prospective 30,546
The risk of postmenopausal breast cancer was reduced
in women in the highest quartile of HDL-C
(>1.64 mmol L−1) compared with women in the lowest
quartile (<1.20 mmol L−1; RR = 0.73 (0.55–0.95)).
No association was found in premenopausal women.
Li et al. [23] 2017 Retrospective 1044
Decreased HDL-C levels showed significant
association with worse overall survival
(HR = 0.528 (0.302–0.923)).
Li et al. [28] 2018 Case–control
Total: 3537
Cases: 1054
Controls: 2483
The levels of LDL-C and HDL-C were lower in breast
cancer patients than controls (p < 0.001).
His et al. [24] 2017 Case–control
Total: 1626
Cases: 583
Controls: 1043
No association between LDL-C or HDL-C and breast
cancer risk or survival.
Martin et al. [14] 2015 Case–control
Total: 837
Cases: 279
Controls: 558
HDL-C was positively associated (75th vs. 25th
percentile: 23% higher, p = 0.05) and non-HDL-C was
negatively associated (75th vs. 25th percentile: 19%
lower, p = 0.03) with breast cancer risk.
Llanos et al. [22] 2012 Case–control
Total: 199
Cases: 97
Controls: 102
Increasing levels of LDL-C were inversely associated
with breast cancer risk (OR = 0.41 (0.21–0.81)).
Lower levels of HDL-C were associated with a
significant increase in breast cancer risk
(OR = 1.99 (1.06–3.74)).
Yadav et al. [29] 2012 Case–control
Total: 139
Cases: 69
Controls: 70
Postmenopausal breast cancer patients had higher
LDL-C levels (p < 0.001) and lower HDL-C levels
(p = 0.025) than controls. No significant changes in
premenopausal women.
Kim et al. [26] 2009 Case–control
Total: 2070
Cases: 690
Controls: 1380
Protective effect of HDL-C on breast cancer was only
observed among premenopausal women (OR = 0.49
(0.33–0.72) for HDL-C ≥ 60 vs. <50 mg dL−1 (p < 0.01)).
J. Clin. Med. 2019, 8, 853 4 of 21
Table 1. Cont.
Reference Year Study Design Participants Main Findings
Owiredu et al. [30] 2009 Case–control
Total: 200
Cases: 100
Controls: 100
Increased LDL-C levels in postmenopausal breast
cancer patients vs. controls (p < 0.05). No significant
changes in premenopausal women.
No changes in HDL-C levels between cases
and controls.
Michalaki et al.
[31] 2005 Case–control
Total: 100
Cases:56
Controls: 44
A decrease in HDL-cholesterol was observed in
patients with breast cancer vs. controls (p < 0.05).
LDL-C = low-density lipoprotein cholesterol, HDL-C = high-density lipoprotein cholesterol, ER = estrogen receptor,
OR = odds ratio, RR = risk ratio, and HR = hazard ratio. Between brackets, 95% confidence interval.
In summary, although some studies failed to find associations between lipoproteins and breast
cancer, the results of some large clinical trials seem to point to a direct association between LDL-C
and breast cancer risk as well as an inverse association between HDL-C and breast cancer risk. It is
important to note that clinical or methodological differences in the design of the studies, including
variation in geographic regions, menopausal status, number of cases, or follow-up length, could
explain the discrepancies found in these studies (summarized in Table 1). For this reason, basic
scientific research can contribute to determining potential underlying mechanisms that may explain
these associations [12].
3. Hypercholesterolemia and Breast Cancer
Diet and obesity are important risk factors for breast cancer development [5,32]. High cholesterol
intake was found to be positively associated with the risk of breast cancer, mainly among postmenopausal
women [33,34]. To address interactions between body weight and dietary fat intake on subsequent
mammary tumor development, a study was performed in which female murine mammary tumor
virus (MMTV)-transforming growth factor α (TGFα) mice consumed a moderately high-fat diet [35].
The MMTV promoter specifically directs expression to the mammary epithelium [36], obtaining a
model that recapitulates human breast cancer progression from early hyperplasia to malignant breast
carcinoma [37]. These mice exhibited mammary tumor latency inversely related to their body fat,
suggesting that body fat may be the mediating factor of the effect of a high-fat diet on mammary
tumor development [35]. Moreover, the expression of a number of proteins associated with leptin and
apoptosis signaling pathways were also affected by diet in the mammary tumors of these animals [38].
Some studies have specifically addressed the role of dietary cholesterol in the regulation of tumor
progression in different experimental mouse models of breast cancer. Llaverias et al. studied the
role of a high-fat/high-cholesterol (HFHC) diet administration in MMTV polyoma middle T (PyMT)
oncogene transgenic mice and found that the HFHC diet accelerated and enhanced tumor progression
in these mice [39]. Plasma cholesterol levels were reduced during tumor development but not prior to
its initiation, providing new evidence for an increased utilization of cholesterol by tumors and for its
role in tumor formation [39]. Another group administered an HFHC diet to female immunodeficient
mice implanted orthotopically with MDA-MB-231 cells and found that diet induced angiogenesis and
accelerated breast tumor growth in this model of breast cancer [40].
The role of dyslipidemia in breast cancer growth and metastasis was also explored in
hypercholesterolemic apolipoprotein E knockout mice (apoE–/–) fed an HFHC diet and injected
with non-metastatic Met-1 and metastatic Mvt-1 mammary cancer cells derived from PyMT mice and
c-Myc/vegf tumor explants, respectively [41]. The apoE glycoprotein is a structural component of all
lipoprotein particles other than LDL, and it acts as a ligand of lipoprotein receptors and participates
in the uptake of lipids into cells. The absence of apoE leads to the accumulation of cholesterol and
triglycerides in plasma [42]. ApoE–/– mice exhibited increased tumor growth and displayed a greater
number of spontaneous metastases to the lungs. The results in tumor growth were only observed
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when an HFHC diet was administered to the mice, not when they were fed a standard chow diet [41].
Therefore, although the uptake of cholesterol via apoE was blocked, other adipocyte apoE-independent
receptors, such as LDL receptor (LDLR) [43], may be involved in the cholesterol uptake by cancer
cells. Moreover, the phosphoinositide 3-kinase (PI3K)/Akt pathway, involved in proinflammatory
and cell proliferation signals, was found to be one mediator of the tumor-promoting activity of
hypercholesterolemia [41].
Whereas the selection of HFHC diets for these studies reflects current dietary trends, this approach
has not allowed an evaluation of the specific effect of cholesterol on tumor biology [44]. To directly
address this question, PyMT mice were administered a high-cholesterol diet from weaning and
developed palpable tumors earlier than mice on a control chow diet were [45]. High-cholesterol diet
administration to mice injected with different breast cancer cell lines (human breast cancer HTB20
and MDA-MB-231, and the mouse breast cancer cell line 4 T1) also promoted breast tumor growth.
Tumors of animals in the high-cholesterol diet group showed a higher proliferative ratio than those
from chow-fed mice, and lung metastasis was increased [46].
4. 27-Hydroxycholesterol and Breast Cancer
Estrogen receptor α-induced signal transduction controls the growth of most breast cancers [47].
27-hydroxycholesterol (27-HC), one of the most prevalent oxysterols, was identified as an endogenous
selective ER modulator (SERM) and liver X receptor (LXR) agonist [48]. This oxysterol is generated
enzymatically from cholesterol by the P450 enzyme sterol 27-hydroxylase CYP27A1. CYP27A1 is
abundant in the liver, but it is also expressed in the intestine, vasculature, brain, and macrophages.
27-HC is mainly transported in association with HDL and LDL, primarily in the esterified form [49].
Regarding its catabolism, 27-HC is hydroxylated by oxysterol 7α-hydroxylase CYP7B1, which is also
abundant in the liver [50].
The first evidence for 27-HC’s role in breast cancer began with studies that found that it stimulated
the growth of ER-positive MCF-7 cells but not that of ER-negative MCF-10 cells. The effect of a
concentration of 1–2 µM of 27-HC was similar to that of 1–2 nM of 17β-estradiol [51]. The proliferative
role of 27-HC in vitro on MCF-7 cells was also confirmed by others, who also reported that 27-HC
increased tumor growth in vivo in PyMT mice and in murine or human cancer cell xenografts [45,52].
27-HC was also found to hasten metastasis to the lungs, an effect that implicated LXR activation [45].
27-HC also hastened myeloid immune cell functions, as it was found that this oxysterol increased the
number of polymorphonuclear neutrophils and γδ T cells as well as decreased cytotoxic CD8+ T cells
within tumors and metastatic lesions [53].
In human breast cancer tissue, 27-HC concentration was found to increase because of decreased
catabolism, sinceCYP7B1 gene expression was downregulated, whereasCYP27A1 remained unchanged.
Moreover, increased CYP7B1 mRNA was correlated with better survival [52]. Consistently, Nelson
et al. found increased CYP27A1 protein expression in higher grade tumors [45]. Nevertheless, the first
prospective epidemiological study on prediagnosis of circulating 27-HC and breast cancer risk showed
an inverse association between blood 27-HC and breast cancer risk among postmenopausal women.
The authors hypothesized that 27-HC-associated inhibition of estradiol–ER binding outweighed
27-HC’s agonistic effect in human breast cancer [54].
Unlike humans, mice do not normally become severely hypercholesterolemic when fed an HFHC
diet [44]. To circumvent this limitation, breast cancer cells were implanted in mice in which the mouse
Apoe gene was replaced with the human APOE3 allele, which codes for the most frequent human
isoform. The animals on an HFHC diet exhibited both increased cholesterol and 27-HC in plasma as
well as promotion of larger tumors, effects that were partially reversed by treatment with the CYP27A1
inhibitor GW273297X [45].
Several studies investigated the potential mechanisms involved in 27-HC-induced breast cancer
development. First, 27-HC inhibited p53 protein and activity in MCF-7 cells via ER. The oxysterol
increased p53 regulator mouse double minute 2 (MDM2) levels and enhanced interaction between
J. Clin. Med. 2019, 8, 853 6 of 21
p53 and MDM2, suggesting that 27-HC proliferation depended on MDM2-mediated p53 degradation.
Interestingly, estradiol, the main physiological endogenous ligand for ER, which had similar
effects to 27-HC on cell proliferation, had no effect on p53 activity; this demonstrates that 27-HC
may contribute to ER-positive breast cancer progression via different mechanisms compared with
known estrogens [55]. Another study found that 27-HC increased Myc protein stability (a critical
oncogene that can promote proliferation, migration, and invasion of cancer cells) by reducing its
dephosphorylation and ubiquitination for proteasomal degradation [56]. Signal transducer and
activator of transcription (STAT)-3 is an important transcription factor that can target c-Myc, vascular
endothelial growth factor (VEGF), cyclin D1, matrix metalloproteinase (MMP) 2, and MMP9 to promote
the development of cancer involving tumor proliferation, invasion, metastasis, and angiogenesis [57].
27-hydroxycholesterol induced activation of STAT-3, which promoted the angiogenesis of breast cancer
cells via proinflammatory-related reactive oxygen species (ROS)/STAT-3/VEGF signaling [58]. Moreover,
it induced the epithelial–mesenchymal transition (EMT) [59], a mechanism that promotes migration and
invasion, via STAT-3/MMP9 and STAT-3/EMT [60], in both ER-positive and ER-negative breast cancer
cells. Furthermore, 27-HC causes greater macrophage infiltration and exacerbation of inflammation in
the setting of hypercholesterolemia [61], thereby providing a link between inflammation and cancer
development. Collectively, mechanisms involved in 27-HC-promoted progression of breast cancer are
complex. Therefore, seeking effective measures to prevent 27-HC-caused pathogenicity is difficult,
and further studies should be carried out with an emphasis on deeply investigating the potential
mechanisms involved in 27-HC breast cancer promotion [58].
The discovery of 27-HC as an endogenous ER ligand that promotes ER-positive breast tumor
growth could help explain why some breast cancer patients are resistant to aromatase inhibitors [62].
In this way, 27-HC may act as an alternate estrogenic ligand in a low-estrogen environment [63].
Assessments of 27-HC or their metabolic enzymes’ abundance in tumors could aid in personalizing
hormone-based therapy [64].
5. Low-Density Lipoprotein and Breast Cancer
Proliferating cancer cells have an increased cholesterol need. Increased LDLR expression was
demonstrated in breast cancer tissue to increase the uptake of LDL-C from the bloodstream [65]. In vitro,
LDLR gene and protein expression was found increased in ER-negative MDA-MB-231 cells in contrast
to ER-positive MCF-7 cells [66,67]. Accordingly, LDL-C mainly promoted proliferation [68–70] and
migration [46,71] in ER-negative cells, but this was not evident in ER-positive cell lines. This difference
between the two cell types corresponded to a greater ability of ER-negative cells to take up,
store, and utilize exogenous cholesterol because of the increased activity of acyl-CoA:cholesterol
acyltransferase 1 (ACAT1) [68]. The Women’s Intervention Nutrition Study (WINS) found that a
low-fat diet mainly extended relapse-free survival in women with ER-negative breast cancer [72].
At least in part, that ER-negative breast cancer cells differentially uptake and store cholesterol may
explain the differential effect of a low-fat diet on human breast cancer recurrence [68]. Another study
found that LDL-C also induced proliferation in ER-positive BT-474 breast cancer cells [46]. This
discrepancy could be because BT-474 cells usually express the Her2 (ErbB2) receptor [73]; furthermore,
high plasma LDL-C levels were found to be associated with Her2-positive breast cells [20]. It
is noteworthy that the Her2-positive and triple-negative subtypes are the most aggressive breast
cancers [74].
Beyond in vitro studies, tumors from breast cancer cells with high LDLR expression
(murine MCNeuA (Her2-positive) and human MDA-MB-231 (triple-negative), respectively) have
been incrementally grown in immunocompetent (LDLR–/– and apoE–/–) and immunodeficient
(Rag1–/–/LDLR–/– and Rag1–/–/apoE–/–) mouse models of hyperlipidemia with increasing serum LDL
concentrations. Importantly, silencing LDLR in the tumor cells reduced tumor growth [67].
Finally, in human samples, LDLR and ACAT1 were also found to be increased in Her2-positive and
triple-negative tumors compared with luminal A tumors. Her2-positive and triple-negative tumors
J. Clin. Med. 2019, 8, 853 7 of 21
were more cholesteryl ester-rich and had higher histological grades, Ki-67 expression, and tumor
necrosis. Therefore, cholesteryl ester accumulation due to increased LDL-C internalization and
esterification was associated with breast cancer proliferation [75]. In line with these findings, higher
LDLR expression was found to be associated with a worse prognosis in patients who underwent
systemic therapy [67]. Overall, elevated circulating LDL and breast cancer expression of LDLR
have roles, at least in Her2-positive and triple-negative breast cancers, in disease progression and
disease-free survival.
Oxidized Low-Density Lipoprotein and Breast Cancer
Lipid peroxidation is associated with carcinogenesis [76]. Lipid peroxidation metabolites cause
structural alterations in DNA and decrease DNA repair capacity through their direct interaction with
repair enzymes [77]. The oxidation of LDL affects both protein and lipid contents, resulting in the
formation of peroxidation metabolites. Patients with breast cancer exhibited elevated serum levels
of oxidized LDL (oxLDL) [78]. Moreover, serum oxLDL levels were associated with increased breast
cancer risk [78]. Oxidized LDL was also reported to trigger pro-oncogenic signaling in MCF10A cells;
concretely, cells treated with oxLDL showed a dose-dependent stimulation of proliferation mediated by
stimulation of the microRNA miR-21, which, in turn, activated the related proinflammatory PI3K/Akt
signaling pathways [79].
OxLDL lecithin-like receptor 1 (OLR1) is the main receptor for internalization of oxLDL. It is
overexpressed in human breast cancer and positively correlates to tumor stage and grade [80].
A microarray analysis of hearts of Olr1 KO mice compared with wild-type mice showed a reduction in
the expression of nuclear factor κB (NF-κB) target genes involved in cellular transformation (regulation
of apoptosis, proliferation, wound healing, defense response, immune response, and cell migration)
as well as an inhibition of key enzymes involved in lipogenesis. The human breast cancer cell line
HCC1143 showed increased OLR1 expression compared with the normal mammary epithelial cell line
MCF10A [81]. Forced overexpression of OLR1 in both cell lines resulted in upregulation of NF-κB
and its target pro-oncogenes involved in the inhibition of apoptosis (BCL2, BCL2A1, and TNFAIP3)
and regulation of the cell cycle (CCND2) in HCC1143 cells. Moreover, upregulation of OLR1 in breast
cancer cell lines enhanced cell migration [81,82]. In line with these findings, OLR1 depletion by
siRNAs, or ORL1 inhibition by antibodies or a recombinant OLR1 protein, significantly suppressed
the invasion and migration of breast cancer cells [81–83]. TBC1D3 is a hominoid-specific oncogene
that also regulates migration of human breast cancer cells. TBC1D3 was found to stimulate the
expression of OLR1, and this TBC1D3-induced OLR1 expression was regulated by tumor necrosis
factor α (TNFα)/NF-κB signaling [84]. Therefore, OLR1 may function in special situations, such as
obesity and chronic inflammation, to increase breast cancer susceptibility.
6. High-Density Lipoprotein and Breast Cancer
Controversy exists about the association between HDL-C levels and breast cancer risk, as detailed
in Section 2. In the present section, experimental data evaluating the role of HDL in breast cancer
development are reviewed. In vitro analyses have shown that HDL stimulated proliferation in both
ER-positive [69,85] and ER-negative breast cancer cell lines [69] in a dose-dependent manner, but
ER-negative cells showed a higher response [69]. Human HDL3 also induced migration and activated
Akt and extracellular signal-regulated kinases (ERK)1/2 signal transduction pathways in both MCF7
and MDA-MB-231 cells [86].
The scavenger receptor class B type I (SR-BI) acts as an HDL receptor and mediates its cholesterol
uptake in breast cancer cells [87]. The receptor SR-BI is abundantly expressed in human breast
cancer tissue compared with adjacent normal tissue [88]. Moreover, high SR-BI expression was
found related to tumor aggressiveness and poor prognosis in breast cancer [75,89,90], whereas
knockdown of SR-BI in vitro attenuated Akt activation and inhibited breast cancer cell proliferation
and migration [86]. Moreover, HDL-induced proliferation was blocked in transfected MCF-7 cells with
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a mutant, nonfunctional SR-BI [88]. Beyond in vitro studies, mice injected with SR-BI-knockdown
breast cancer cells showed a decreased tumor burden, accompanied with reduced Akt and ERK1/2
activation, reduced angiogenesis, and increased apoptosis [86]. Therefore, cholesteryl ester entry via
HDL-SR-BI and Akt signaling seems to play a critical role in the regulation of cellular proliferation
and migration and tumor growth. SR-BI was also found to increase concomitantly with an increased
number and size of tumors in PyMT mice fed an HFHC diet compared with those fed a chow diet.
However, cholesterol was not found accumulated in the mammary tumors, suggesting that even if
tumor cholesterol uptake was increased, cholesterol was probably metabolized to sustain a high level
of proliferation [39].
Serum HDL particles contain either a single copy or multiple copies of apolipoprotein A-I
(apoA-I), the most abundant HDL apolipoprotein [91]. Apolipoprotein A-I plays a role in promoting
cholesterol release from cells; possesses anti-inflammatory, antioxidant, and antiapoptotic properties;
and influences innate immunity [92]. The levels of apoA-I have normally been found to be inversely
associated with breast cancer risk [19,93,94], although one study found that apoA-I was positively
associated with breast cancer [21]. Our group showed that human apoA-I-containing HDL could not
hinder breast tumor development in PyMT mice. While overexpression of human apoA-I reduced the
levels of oxLDL, 27-HC levels were increased, which could promote tumor growth [95]. Concerning
apoA-II, the second major protein constituent of HDL [96], our research group showed that human
apoA-II-containing HDL increased the breast tumor burden in PyMT mice (Figure 1A) (unpublished
results). These results may be related with the apoA-II-mediated alteration in HDL remodeling,
decreased capacity to protect against LDL oxidative modification and its proinflammatory actions,
and postprandial hyperlipidemia (Figure 1B) [97,98].
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Figure 1. Effects of human apolipoprotein A-II (hApoA-II) overexpression on tumor development
in polyoma middle T (PyMT) mice. PyMT mice were backcrossed with hApoA-II transgenic (TG)
mice on a C57BL/6 background. The mice were maintained on a regular chow diet until 19 weeks of
age, when they were euthanized, and the mammary glands were excised and weighed. Serum lipids
were determined after an overnight fasting period and 3 h after a 0.15 mL dose of olive oil by oral
gavage. A) Mammary gland weight. B) Serum lipid levels in fasting and postprandial conditions
(TG = triglycerides, and HDL-C = high-density lipoprotein cholesterol). Values shown represent the
mean ± SEM. A t-test was performed to determine the statistical significance between groups. * p < 0.05
vs. PyMT mice.
Dysfunctional High-Density Lipoprotein and Breast Cancer
Under conditions of oxidative stress, HDL can be oxidatively modified, and these modifications
may have an effect on HDL function. Hypochlorite-oxidized HDL was found to stimulate cell
proliferation, migration, invasion, and adhesion in vitro, involving the protein kinase C (PKC) pathway,
which regulates numerous cellular responses including cell proliferation and the inflammatory response.
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This modified HDL promoted breast cancer cell pulmonary and hepatic metastasis compared with
normal HDL in vivo. Interestingly, in this study, normal HDL reduced the metastasis of MCF7 cells in
the liver compared with control animals in which HDL was not injected [99].
In patients with type 2 diabetes mellitus (T2DM), HDL can be modified into dysfunctional glycated
HDL and oxidized HDL [100]. Indeed, T2DM patients have a 20% increased risk of breast cancer
compared with nondiabetic subjects [101]. In this context, diabetic HDL was found to have a stronger
capability to promote cell proliferation, migration, and invasion of breast cancer cells through the Akt,
ERK, and p38 mitogen-activated protein kinase (MAPK) pathways. These observations were also found
in glycated and oxidized HDL produced in vitro, compared with normal HDL [102]. Pretreatment
with diabetic, glycated, and oxidized HDL also promoted the metastasis capacity of breast cancer
cells in vivo, and it increased their capacity of adhesion to human umbilical vein endothelial cells
(HUVECs) and attachment to the extracellular matrix in vitro, compared with normal HDL. These
effects mainly were due to elevated PCK activity, which, in turn, could stimulate secretion of integrins,
which are important in promoting breast cancer metastasis [103]. Similarly, HDL isolated from patients
with breast cancer complicated with T2DM promoted an increase in breast cancer cell adhesion to
HUVECs and stimulated higher intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1) expression on the cell surfaces of breast cancer cells and HUVECs, along with
the activation of PKC, compared with HDL isolated from breast cancer patients. However, in breast
cancer patients complicated with T2DM, a lower expression of ICAM-I and VCAM-I was found in their
tumor tissue, which may contribute to the metastasis of tumor cells [104]. Collectively, associations
between T2DM and breast cancer could be attributed, in part, to alterations in HDL structure and
composition and their proinflammatory actions.
7. Effects of Cholesterol-Lowering Therapies on Breast Cancer
The studies reviewed indicate that cholesterol and its main metabolite, 27-HC, may increase breast
cancer development and metastasis. To address this, cholesterol-lowering drugs have emerged as
potential therapies to reverse the deleterious effects of impaired cholesterol metabolism in breast cancer.
7.1. Statins
Statins are inhibitors of the enzyme hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR),
which catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of cholesterol
synthesis [105]. In humans, the effect of statins in cancer prevention and treatment remains controversial
(Table 2). The use of lipid-lowering drugs, and more concretely, statins, was found to be associated
with a reduced risk of breast cancer in older women [106]. Specifically, the use of lipophilic statins but
not hydrophilic statins were found to significantly reduce the risk of breast cancer in Thai women [107].
Conversely, other studies, including a large Mendelian randomization study, failed to find a protective
effect of statins against breast cancer risk [108–113], or they even found a positive association between
long-term use of statins and increased risk of breast cancer [114]. In contrast, treatment with statins
seems to have a more important effect in protecting against breast cancer recurrence and death [115–122].
Considering the type of statin, lipophilic statins were mainly found to be associated with a reduced
risk of breast cancer recurrence or mortality [123–125], although hydrophilic statin use was also found
to be associated with improved progression-free survival compared with no statin use in inflammatory
breast cancer patients [126]. Taken together, HMGCR inhibitors do not seem to protect against breast
cancer development, but statins, and more concretely, lipophilic statins, could be a good strategy for
protecting against breast cancer recurrence and death.
Statins also exert antiproliferative and cytotoxic effects on breast cancer cells in vitro by increasing
apoptosis, autophagy, and cell cycle arrest [127,128]. However, only lipophilic statins show anticancer
activity [129], and the ER-negative phenotype seems to be more sensitive than those that overexpress
ER [129,130]. ER-positive cell resistance to statin treatment is associated with high expression of
cholesterol biosynthesis genes [131].
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In vivo studies have also reported controversial results. Atorvastatin was able to reduce the level
of circulating cholesterol, and it attenuated enhanced tumor growth and lung metastasis associated
with an HFHC diet in a transgenic model in which the murine Apoe gene was replaced with the human
APOE3 allele and injected with ER-positive E0771 murine mammary cancer cells [45,53]. Moreover,
simvastatin and fluvastatin treatments were found to inhibit tumor growth in mice inoculated with
breast cancer cells [129,132], and fluvastatin was also found to reduce the metastatic burden in a
murine breast cancer metastasis model [133]. The mechanisms of action of simvastatin included
the inhibition of NF-κB transcription factor, which attenuated expression of antiapoptotic BclXL
and derepressed expression of the antiproliferative/proapoptotic tumor suppressor PTEN, which
reduced the phosphorylation of Akt, resulting in decreased cancer cell proliferation and survival [132].
In contrast, statin treatment failed to reduce plasma cholesterol levels or tumor growth in mice injected
with breast cancer cells on an HFHC diet [46] or other models of breast cancer in mice and rats [134].
An explanation for these negative results could be that mice are generally unresponsive to statins [135].
Finally, an interesting study investigated the biological effect of short-term lipophilic fluvastatin
exposure on in situ and invasive breast cancer through paired tissue, blood, and imaging-based
biomarkers in women with a diagnosis of ductal carcinoma in situ or stage 1 breast cancer. Fluvastatin
exposure showed reduced tumor proliferation and increased apoptotic activity in high-grade breast
cancer, concomitant with a reduction of cholesterol levels [136]. An upregulation of HMGCR was
observed in breast cancer patients after two weeks of atorvastatin treatment, which was interpreted
as activation of the negative feedback loop controlling cholesterol synthesis. Moreover, in tumors
expressing HMGCR before treatment with atorvastatin, the proliferation marker Ki67 was found to be
downregulated. In summary, these results suggested that HMGCR was targeted by statins in breast
cancer cells in vivo, and that statins could have antiproliferative effects, mostly in HMGCR-positive
breast cancers [137]. Importantly, atorvastatin was also found to decrease serum 27-HC and CYP27A1
expression in tumors of breast cancer patients [138].
Table 2. Clinical and epidemiological studies linking statin treatment to breast cancer risk.
Reference Year Study Design Participants Main Findings
Ference et al. [113] 2019 Mendelianrandomization 654,783
Genetic inhibition of HMGCR did not affect breast
cancer risk.
Islam et al. [109] 2017 Meta-analysis 121,399 There was no association between statin use and breastcancer risk.
Liu et al. [123] 2017 Meta-analysis 197,048
Significant protective effects of lipophilic statin use,
but not hydrophilic statins, against cancer-specific
mortality (HR = 0.57 (0.46–0.70)).
Mansourian et al.
[116] 2016 Meta-analysis 124,669
Significant reduction in breast cancer recurrence
(OR = 0.792 (0.735–0.853)) and death (OR = 0.849
(0.827–0.870)) among statin users.
Manthravadi et al.
[124] 2016 Meta-analysis 75,684
Lipophilic statin use was associated with improved
recurrence-free survival (HR = 0.72 (0.59–0.89)).
Wu et al. [119] 2015 Meta-analysis 144,830
There was a significantly negative association between
prediagnosis statin use and breast cancer mortality
(for overall survival: HR = 0.68 (0.54–0.84), and for
disease-specific survival (HR = 0.72 (0.53–0.99)). There
was also a significant inverse association between
postdiagnosis statin use and breast cancer
disease-specific survival (HR = 0.65 (0.43–0.98)).
No significant association was detected between statin
use and breast cancer risk.
Undela et al. [111] 2012 Meta-analysis >2.4 million Statin use and long-term statin use did notsignificantly affect breast cancer risk.
Bonovas et al. [108] 2005 Meta-analysis 327,238 Statin use did not significantly affect breast cancer risk.
Dale et al. [112] 2005 Meta-analysis 86,936 Statins did not reduce the incidence of breast cancer.
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Table 2. Cont.
Reference Year Study Design Participants Main Findings
Borgquist et al.
[115] 2017 Prospective 8010
Initiation of cholesterol-lowering medication in
postmenopausal women with early stage, hormone
receptor-positive invasive breast cancer during
endocrine therapy was related to improved
disease-free survival (HR = 0.79 (0.66–0.95)), breast
cancer-free interval (HR = 0.76 (0.60–0.97)), and distant
recurrence-free interval (HR = 0.74 (0.56–0.97)).
Murtola et al. [122] 2014 Prospective 31,236
Both postdiagnostic and prediagnostic statin uses were
associatedwith a lowered risk of breast cancer death
(HR = 0.46 (0.38–0.55) and
HR = 0.54 (0.44–0.67), respectively).
Brewer et al. [126] 2013 Prospective 723
Hydrophilic statins were associated with significantly
improved progression-free survival compared with no
statin (HR = 0.49 (0.28–0.84)) in inflammatory breast
cancer patients.
Ahern et al. [125] 2011 Prospective 18,769
Significant reduction in breast cancer recurrence
among patients using simvastatin after 10 y of follow
up (adjusted HR = 0.70 (0.57–0.86)).
Cauley et al. [106] 2003 Prospective 7528
Older women who used statins had a reduced risk of
breast cancer (RR = 0.28 (0.09–0.86), adjusted for age
and body weight) compared with nonusers.
Shaitelman et al.
[120] 2017 Retrospective 869
Statin use was significantly associated with overall
survival (HR = 0.10 (0.01–0.76)) in triple-negative
breast cancer.
Smith et al. [121] 2017 Retrospective 6314
Prediagnostic statin use was associated with breast
cancer-specific mortality (HR = 0.81 (0.68–0.96)). This
reduction was greatest in statin users with ER-positive
tumors (HR = 0.69 (0.55–0.85)).
Anothaisintawee
et al. [107] 2016 Retrospective 15,718
Using lipophilic statins, but not hydrophilic statins,
could significantly reduce the risk of breast cancer
(risk difference = –0.0034
(–0.006,–0.001) lipophilic statin users vs. nonusers).
Mc Menamin et al.
[139] 2016 Retrospective 15,140
There was no evidence of an association between statin
use and breast cancer-specific death.
Sakellaki et al.
[117] 2016 Retrospective 610
Statins may be linked to a favorable outcome in early
breast cancer patients,
especially in younger age groups
(HR = 0.58 (0.36–0.94)).
Chae et al. [118] 2011 Retrospective 703
Significant reduction in breast cancer recurrence
among patients who used statins (HR = 0.43
(0.26–0.70)). No association was found regarding
overall survival.
Schairer et al. [110] 2018 Case–control
Total: 228,973
Cases: 30,004
Controls: 198,969
Statin use did not significantly affect breast cancer risk.
McDougall et al.
[114] 2013 Case–control
Total: 2886
Cases: 916 IDC +
1068 ILC
Controls: 902
Current users of statins for ≥10 y had increased risk of
IDC (OR = 1.83 (1.14–2.93)) and ILC (OR = 1.97
(1.25–3.12)) compared with never users of statins.
OR = odds ratio, RR = risk ratio, HR = hazard ratio, y = years, IDC = invasive ductal carcinoma; and ILC = invasive
lobular carcinoma. Between brackets, 95% confidence interval.
7.2. Ezetimibe
Ezetimibe is a drug that specifically targets intestinal Niemann-Pick C1-Like 1 (NPC1L1) and
mediates the inhibition of intestinal sterol absorption [140]. Few studies have explored the effects of
ezetimibe on breast cancer. However, considering that statins may have little effect on plasma cholesterol
in mice [135], ezetimibe’s action on breast cancer development is of interest. A study by Pelton et al.
investigated the effects of ezetimibe administered in an HFHC diet on breast cancer development in an
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orthotopic breast tumor model, in which mice were implanted with MDA-MB-231 cells. Ezetimibe was
able to reduce tumor volume, proliferation, and angiogenesis and increase apoptosis compared with
the HFHC-fed mice, achieving similar results to those in mice fed a low-fat/low cholesterol (LFLC) diet.
These results were accompanied with a reduction in circulating cholesterol levels, but intratumoral
cholesterol levels remained unchanged [40].
To our knowledge, the effects of ezetimibe treatment on breast cancer risk or mortality have
not been studied. Only Kobberø Lauridsen et al. explored the effects of genetic variants of NPC1L1
(–133A>G and V1296V T>C), mimicking treatment with ezetimibe, on breast cancer risk. These
researchers found that NPC1L1 variants were not associated with the risk of breast cancer [141].
7.3. Phytosterols
Plant sterols, or phytosterols, lower serum LDL-C levels by reducing intestinal cholesterol
absorption [142]. Several in vivo studies have tested the efficacy of dietary phytosterol in breast
cancer development. Female severe combined immunodeficiency (SCID) mice supplemented with
2% phytosterols and injected with MDA-MB-231 cells exhibited a reduction in serum cholesterol,
accompanied with a reduction in tumor size and metastasis to lymph nodes and lungs [143].
In ovariectomized athymic mice injected with MCF-7 cells, supplementation with β-sitosterol,
the most common phytosterol, was also able to reduce tumor size [144]. Furthermore, phytosterol
supplementation could decrease both the development of mammary hyperplastic lesions and tumor
burden in PyMT mice fed an HFHC diet. This protective effect was not observed in mice fed an LFLC
diet. A potential mechanism of action of phytosterol was the prevention of lipoprotein oxidation [145].
Numerous experimental in vitro studies showed that phytosterols functioned as anticancer
compounds acting on host systems to affect tumor surveillance or on tumors to affect tumor cell
biology. Mechanisms affecting the tumors include slowing of cell cycle progression, induction of
apoptosis, inhibition of tumor metastasis, altered signal transduction, and activation of angiogenesis.
Host influences comprise enhancing immune recognition of cancer, influencing hormonal-dependent
growth of endocrine tumors, and altering cholesterol metabolism (reviewed in [146,147]).
7.4. Other Therapies
Fibrates are agonists of the peroxisome proliferator-activated receptor α (PPARα), which stimulate
the expression of genes involved in fatty acid and lipoprotein metabolism, resulting in a shift
from hepatic fat synthesis to fat oxidation. Fibrates are used as therapeutic agents for treating
dyslipidemia [148]. A meta-analysis of 17 long-term, randomized, placebo-controlled trials found that
fibrates had a neutral effect on breast cancer and other cancer outcomes [149].
The levels of HDL-C and apoA-I are inversely related to cardiovascular risk [150]. The beneficial
effects of HDL have largely been attributed to apoA-I, and researchers have sought apoA-I mimetic
peptides as therapeutic agents based on physical–chemical and biological properties [151]. To our
knowledge, a study from our group was the only one to analyze the effects of apoA-I mimetics on
breast cancer. In that study, the apoA-I mimetic peptide D-4F was administered to PyMT female mice,
and the treatment significantly increased tumor latency and inhibited the development of tumors.
D-4F was unable to reduce the levels of 27-HC in the tumors, but it decreased the plasma levels of
oxLDL and prevented the oxLDL-mediated proliferative response in MCF-7 cells, suggesting that D-4F
inhibited breast cancer by protecting against LDL oxidative modifications [95].
8. Concluding Remarks
Results of some large clinical studies indicate a direct association for LDL-C and an inverse
association for HDL-C and breast cancer risk; however, these findings have not been reproduced in all
epidemiological studies and are still debated. Basic research studies have determined the important
role of cholesterol, especially the 27-HC metabolite, and its transporters in breast cancer development.
Both LDL and HDL, and their modified forms (oxLDL and oxidized and glycated HDL), may promote
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breast cancer via several mechanisms. Investigations in breast cancer cells and experimental models
in vivo have demonstrated an interplay among modified lipoproteins, proinflammatory signaling
pathways, and breast cancer tumorigenic processes (summarized in Figure 2). Cholesterol can be
esterified or metabolized to 27-HC, which has been hypothesized to be responsible for stimulating the
proliferation of ER-positive breast cancer cells rather than cholesterol (Figure 2). Oxidized LDL as well
as oxidized and glycated HDL induce different OLR1 and SR-BI downstream inflammation-related
pathways, thereby inhibiting apoptosis and enhancing cell proliferation and migration. Therefore,
considering the important role of cholesterol in breast cancer development, cholesterol-lowering drugs
and apoA-I mimetics, which possess antioxidant and anti-inflammatory properties, could emerge as
potential therapies for preventing the deleterious effects of high cholesterol in breast cancer. Lipophilic
statins seem a good strategy for protecting against breast cancer recurrence and death. However, more
studies in humans are necessary to evaluate the role of other therapies, such as ezetimibe, phytosterols
or fibrates, on breast cancer risk and prognosis.
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Figure 2. Mechanisms by which low-density lipoprotein (LDL), high-density lipoprotein (HDL),
and their modified forms induce proliferation and migration and reduce apoptosis in breast cancer
cells. OLR1 = OxLDL lecithin-like receptor 1, LDLR = LDL receptor, SR-BI = scavenger receptor class B
type I, HMGCR = hydroxy-methyl-glutaryl-coenzyme A reductase, ACAT1 = acyl-CoA:cholesterol
acyltransferase 1, 27-HC = 27-hydroxycholesterol, ERK1/2 = extracellular signal-regulated kinases 12 ,
NFκB = nuclear factor κB, and ER/LXR = estrogen receptor/liver X receptor.
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